CYC116Potent Aurora A/B inhibitor CAS# 693228-63-6 |
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- SCH-1473759
Catalog No.:BCC1934
CAS No.:1094069-99-4
- Reversine
Catalog No.:BCC1892
CAS No.:656820-32-5
- AZD1152
Catalog No.:BCC1393
CAS No.:722543-31-9
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 693228-63-6 | SDF | Download SDF |
PubChem ID | 6420138 | Appearance | Powder |
Formula | C18H20N6OS | M.Wt | 368.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine | ||
SMILES | CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4 | ||
Standard InChIKey | GPSZYOIFQZPWEJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | CYC116 is a potent inhibitor of Aurora A and B with Ki value of 8 nM and 9.2 nM, respectively. | |||||
Targets | Aurora A | Aurora B | ||||
IC50 | 8 nM | 9.2 nM |
CYC116 Dilution Calculator
CYC116 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.714 mL | 13.57 mL | 27.14 mL | 54.28 mL | 67.85 mL |
5 mM | 0.5428 mL | 2.714 mL | 5.428 mL | 10.856 mL | 13.57 mL |
10 mM | 0.2714 mL | 1.357 mL | 2.714 mL | 5.428 mL | 6.785 mL |
50 mM | 0.0543 mL | 0.2714 mL | 0.5428 mL | 1.0856 mL | 1.357 mL |
100 mM | 0.0271 mL | 0.1357 mL | 0.2714 mL | 0.5428 mL | 0.6785 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 44 and 19 nM respectively for Aurora A and B in cancer cells
Ki: 8.0 and 9.2 nM for aurora A and B, respectively
The aurora kinases are a family of serine-threonine kinases that interact with components of the mitotic apparatus and that regulate aspects of centrosome maturation, bipolar spindle assembly, chromosome segregation, and cytokinesis. CYC116 has been discoverd as a novel N-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitor.
In vitro: The anticancer effects of CYC116 were shown to emanate from cell death following mitotic failure and increased polyploidy as a consequence of cellular inhibition of aurora A and B kinases. Moreover, CYC116 was also assessed against other kinases [1].
In vivo: Preliminary in vivo assessment showed that CYC116 was orally bioavailable and possessed anticancer activity. The mean relative tumor volumes of mice receiving CYC116 at both dose levels were less than those of vehicle-treated mice for the duration of the study period [1].
Clinical trials: CYC116 is currently undergoing evaluation in Phase I clinical trials.
Reference:
[1] Wang S, Midgley CA, Scaërou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010;53(11):4367-78.
- H-Ile-OtBu.HCl
Catalog No.:BCC2965
CAS No.:69320-89-4
- (R)-baclofen
Catalog No.:BCC4503
CAS No.:69308-37-8
- 12-Aminolauric acid
Catalog No.:BCC8436
CAS No.:693-57-2
- 3-beta-O-(cis-p-Coumaroyl)maslinic acid
Catalog No.:BCN1375
CAS No.:69297-40-1
- 8-O-Acetylharpagide
Catalog No.:BCN4256
CAS No.:6926-14-3
- Harpagide
Catalog No.:BCN4996
CAS No.:6926-08-5
- N-Benzylcinchonidinium chloride
Catalog No.:BCC9094
CAS No.:69257-04-1
- 1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid
Catalog No.:BCN7205
CAS No.:69251-99-6
- Pinoresinol 4-O-beta-D-glucopyranoside
Catalog No.:BCN1376
CAS No.:69251-96-3
- Osthol hydrate
Catalog No.:BCN1377
CAS No.:69219-24-5
- 2'-Hydroxy-4'-methylacetophenone
Catalog No.:BCN7751
CAS No.:6921-64-8
- (±)-Hexanoylcarnitine chloride
Catalog No.:BCC6680
CAS No.:6920-35-0
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
- 2-Benzylaminopyridine
Catalog No.:BCC8565
CAS No.:6935-27-9
- Obtucarbamate A
Catalog No.:BCN3936
CAS No.:6935-99-5
- Galanthamine hydrochloride
Catalog No.:BCC8277
CAS No.:5072-47-9
- Boc-D-Thr(Bzl)-OH
Catalog No.:BCC3454
CAS No.:69355-99-3
- Pendulone
Catalog No.:BCN8248
CAS No.:69359-09-7
- Schisanhenol
Catalog No.:BCN2508
CAS No.:69363-14-0
- Sulbactam sodium
Catalog No.:BCC4852
CAS No.:69388-84-7
- Lappaol H
Catalog No.:BCN8415
CAS No.:69394-18-9
- Amonafide
Catalog No.:BCC1249
CAS No.:69408-81-7
- SB505124
Catalog No.:BCC5087
CAS No.:694433-59-5
- 17-PA
Catalog No.:BCC7452
CAS No.:694438-95-4
Matrine and CYC116 synergistically inhibit growth and induce apoptosis in multiple myeloma cells.[Pubmed:25804197]
Chin J Integr Med. 2015 Aug;21(8):635-9.
OBJECTIVE: To investigate whether CYC116 can potentiate matrine-dependent growth inhibition and apoptosis in multiple myeloma (MM) cells. METHODS: The dose response relationship of matrine to dexamethasone-resistant and dexamethasone-sensitive MM cells was first established. Myeloma RPMI8226 cells were treated with matrine alone or combined with CYC116 for 24 h. Cell proliferation was measured using an MTT assay and apoptosis induction was evaluated by flow cytometry. Activation of the caspase pathway and expression of apoptosis regulator proteins were detected by Western blotting. RESULTS: Matrine significantly induced growth arrest and apoptosis in both drug-resistant and drug-sensitive MM cells. Treatment with the combination of matrine and CYC116 had a stronger cytotoxic effect on MM cells than did single drug treatments. Enhanced apoptosis observed following the combined treatment of matrine and CYC116 was associated with higher levels of activation of caspase-9, caspase-3, and poly adenosine diphosphate ribose polymerase (PARP) and down-regulation of the anti-apoptotic proteins Bcl-2 and Mcl-1 and the signaling proteins p-Akt and nuclear factor kappaB (NF-kappaB). CONCLUSION: CYC116 enhances the growth inhibitory and apoptotic effects of matrine on MM cells.